Exact Mass: 639.2679476000001
Exact Mass Matches: 639.2679476000001
Found 69 metabolites which its exact mass value is equals to given mass value 639.2679476000001
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Protorifamycin I
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins
N2-iBu-DMT- dG
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.363 5'-O-DMT-N2-ibu-dG (N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyguanosine) is a deoxynucleoside which can be used in the preparation of oligonucleotides[1].
Abivertinib maleate
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Chaxamycin A
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins
25-O-deacetyl-27-O-demethylrifamycin S
C34H41NO11 (639.2679476000001)
(5Z,9alpha,13E,15S)-9-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-11-oxoprosta-5,13-dien-1-oate
(5Z,11alpha,13E,15S)-11-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-9-oxoprosta-5,13-dien-1-oate
(5Z,11beta,13E,15S)-11-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-9-oxoprosta-5,13-dien-1-oate
(5Z,9beta,13E,15S)-9-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-15-hydroxy-11-oxoprosta-5,13-dien-1-oate
(5S,6R,7E,9E,14Z)-6-({(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-5-hydroxy-12-oxoicosa-7,9,14-trienoate
(6Z,8Z,10S,11S,12R,13R,14S,15R,16S,17S,19Z)-11,13,15,17,22-pentahydroxy-18-(hydroxymethyl)-6,10,12,14,16,20,23-heptamethyl-11,12,13,14,15,16,17,18-octahydro-1H-3,25-methano-4-benzazacyclotricosine-1,5,21,26(4H,10H)-tetrone
2-amino-3-[[3-butanoyloxy-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[3-[(E)-dec-4-enoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
DTP3 (TFA)
C28H36F3N7O7 (639.2628182000001)
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1].
n-[2-({2-[(2,4-dicarbamimidamido-3,5,6-trihydroxycyclohexyl)oxy]-4-formyl-4-hydroxy-5-methyloxolan-3-yl}oxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]-2-hydroxy-n-methylacetamide
C23H41N7O14 (639.2711366000001)
4,10,12,14,16,22-hexahydroxy-9-(hydroxymethyl)-3,7,11,13,15,17,21-heptamethyl-23-azatricyclo[22.3.1.0⁵,²⁷]octacosa-1(27),2,4,7,18,20,22,24-octaene-6,26,28-trione
(7e,9s,10s,11r,12r,13r,14r,15r,16s,17s,18e)-2,4,10,12,14,16,22-heptahydroxy-3,7,9,11,13,15,17,25-octamethyl-23-azatricyclo[22.3.1.0⁵,²⁷]octacosa-1(27),2,4,7,18,20,22,24-octaene-6,26,28-trione
n-[(2s,3s,4s,5r,6s)-2-{[(2r,3s,4s,5r)-2-{[(1s,2r,3s,4s,5s,6r)-2,4-dicarbamimidamido-3,5,6-trihydroxycyclohexyl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]-2-hydroxy-n-methylacetamide
C23H41N7O14 (639.2711366000001)
(7e,9s,10s,11r,12r,13r,14r,15r,16s,17s,18e,20z)-2,4,10,12,14,16,22-heptahydroxy-3,7,9,11,13,15,17,25-octamethyl-23-azatricyclo[22.3.1.0⁵,²⁷]octacosa-1(27),2,4,7,18,20,22,24-octaene-6,26,28-trione
7-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-11-hydroxy-8,8,10,12,16-pentamethyl-3-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
[3-(2-aminoethyl)-10-[3-(cyclohexanecarbonyloxy)cyclohexyl]-1-(3-ethyl-6-oxo-2,3-dihydropyran-2-yl)-3,6-dihydroxydeca-1,7,9-trien-4-yl]oxyphosphonic acid
(1s,2z,16z,18e,20s,21s,22r,23s,24s,25r,28r,29s)-6,8,15,21,23,27,28-heptahydroxy-3,7,20,22,24,29-hexamethyl-26-oxa-14-azatetracyclo[23.2.2.1⁹,¹³.0⁵,¹⁰]triaconta-2,5,7,9,12,14,16,18-octaene-4,11,30-trione
C34H41NO11 (639.2679476000001)
(1s,2e,16z,18e,20s,21s,22r,23r,24r,25r,28r)-6,8,15,21,23,27,28-heptahydroxy-3,7,16,20,22,24-hexamethyl-26-oxa-14-azatetracyclo[23.2.2.1⁹,¹³.0⁵,¹⁰]triaconta-2,5,7,9,12,14,16,18-octaene-4,11,30-trione
C34H41NO11 (639.2679476000001)
8-acetyl-1,6,8,11-tetrahydroxy-10-{[2-(2-hydroxypropyl)-4,10-dimethyl-2h,4h,6ah,7h,8h,10h,10ah-pyrano[3,4-d][1,3,6]dioxazocin-8-yl]oxy}-9,10-dihydro-7h-tetracene-5,12-dione
C33H37NO12 (639.2315642000001)